Does Codexis, Inc. (CDXS) Have More Gas After Achieving 52-Week High?

May 22, 2018 - By Michael Collier

Codexis, Inc. (NASDAQ:CDXS) Logo

Investors sentiment decreased to 2.17 in Q4 2017. Its down 0.03, from 2.2 in 2017Q3. It turned negative, as 3 investors sold Codexis, Inc. shares while 15 reduced holdings. 12 funds opened positions while 27 raised stakes. 28.02 million shares or 9.42% more from 25.60 million shares in 2017Q3 were reported.
Schwab Charles Investment Management Incorporated reported 84,581 shares. Virtu Fincl Limited Liability Corporation owns 24,209 shares or 0.01% of their US portfolio. Royal Bancorporation Of Canada accumulated 42,147 shares or 0% of the stock. Metropolitan Life Insurance Comm Ny reported 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). 1.81 million were reported by Vanguard Group. New York State Common Retirement Fund holds 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 34,400 shares. Perkins Capital Mngmt owns 30,000 shares. Baillie Gifford & holds 0.02% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 1.84M shares. Laurion Cap Mgmt Lp accumulated 59,726 shares or 0% of the stock. Tower Capital Ltd Co (Trc) reported 10,400 shares. Parallax Volatility Advisers L P invested in 6,594 shares or 0% of the stock. Stifel Financial has invested 0% in Codexis, Inc. (NASDAQ:CDXS). Ameritas Partners Inc holds 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS) for 2,608 shares. Tiaa Cref Inv Mgmt Ltd Limited Liability Company reported 97,385 shares. Envestnet Asset Management Inc reported 1,662 shares.

Since March 21, 2018, it had 0 insider buys, and 7 selling transactions for $1.73 million activity. Smith David V also sold $62,213 worth of Codexis, Inc. (NASDAQ:CDXS) on Tuesday, April 3. Another trade for 10,206 shares valued at $124,683 was made by KELLEY BERNARD J on Wednesday, March 21. The insider Lalonde James sold 20,000 shares worth $259,930. Aldridge Michael D. had sold 22,000 shares worth $283,945. Another trade for 41,666 shares valued at $464,384 was made by WOLF DENNIS P on Monday, March 26. NICOLS JOHN J sold $259,828 worth of stock or 22,465 shares.

The stock of Codexis, Inc. (NASDAQ:CDXS) hit a new 52-week high and has $14.72 target or 4.00 % above today’s $14.15 share price. The 6 months bullish chart indicates low risk for the $753.35M company. The 1-year high was reported on May, 22 by If the $14.72 price target is reached, the company will be worth $30.13M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.35% or $0.05 during the last trading session, reaching $14.15. About 155,670 shares traded. Codexis, Inc. (NASDAQ:CDXS) has risen 125.77% since May 22, 2017 and is uptrending. It has outperformed by 114.22% the S&P500.

Analysts await Codexis, Inc. (NASDAQ:CDXS) to report earnings on August, 8. They expect $-0.03 earnings per share, up 76.92 % or $0.10 from last year’s $-0.13 per share. After $-0.10 actual earnings per share reported by Codexis, Inc. for the previous quarter, Wall Street now forecasts -70.00 % EPS growth.

Codexis, Inc. (NASDAQ:CDXS) Ratings Coverage

Among 2 analysts covering Codexis (NASDAQ:CDXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Codexis had 2 analyst reports since March 12, 2018 according to SRatingsIntel. The stock of Codexis, Inc. (NASDAQ:CDXS) has “Buy” rating given on Wednesday, May 16 by Stephens. H.C. Wainwright maintained the stock with “Buy” rating in Monday, March 12 report.

More notable recent Codexis, Inc. (NASDAQ:CDXS) news were published by: which released: “Codexis Reports First Quarter 2018 Financial Results” on May 10, 2018, also with their article: “Premarket analyst action – healthcare” published on May 16, 2018, published: “3 High-Growth Stocks That Are Just Getting Started” on May 12, 2018. More interesting news about Codexis, Inc. (NASDAQ:CDXS) were released by: and their article: “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript” published on May 11, 2018 as well as‘s news article titled: “Codexis to Hold First Quarter 2018 Conference Call on May 10” with publication date: May 03, 2018.

Codexis, Inc. discovers, develops, and sells protein catalysts. The company has market cap of $753.35 million. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening. It currently has negative earnings. The firm also provides protein catalyst screening and protein engineering services.

Codexis, Inc. (NASDAQ:CDXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.